ArticleNature communications2022
Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Two cases of durvalumab-induced Evans syndrome in biliary tract cancer.Clinical journal of gastroenterology · 2026Article
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Review
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Tumor-infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors.International journal of cancer · 2026Review
- Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer.Frontiers in immunology · 2026Article
- The evolving role of the immune microenvironment of tumor draining lymph nodes in the development of biomarkers of non-small cell lung cancer.Frontiers in oncology · 2026Review
- Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy.Nature communications · 2025Article
- Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.Human vaccines & immunotherapeutics · 2025Review
- Treatment of NSCLC after chemoimmunotherapy - are we making headway?Nature reviews. Clinical oncology · 2025Review
- Dual aVß8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Tumor Immunity.Neuro-oncology · 2025Article
- B cell-associated research in non-small cell lung cancer: a bibliometric analysis of current landscapes and future directions.Discover oncology · 2025Article
- Innate and adaptive immune features associated with immune-related adverse events.Journal for immunotherapy of cancer · 2025Article
- The role of B cell immunity in lung adenocarcinoma.Genes and immunity · 2025Review
- Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.Journal for immunotherapy of cancer · 2025Article
- B cells and tertiary lymphoid structures in cancer therapy response.BJC reports · 2025Review
- Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.Cancer cell international · 2025Review
- Revealing the role of regulatory b cells in cancer: development, function and treatment significance.Cancer immunology, immunotherapy : CII · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Checkpoint blockade with Pembrolizumab, has demonstrated durable clinical responses in advanced non-small cell lung cancer, however, treatment is offset by the development of high-grade immune related adverse events (irAEs) in some patients. Here, we show that in these patients a deficient Breg checkpoint fails to limit self-reactive T cell enhanced activity and auto-antibody formation enabled by PD-1/PD-L1 blockade, leading to severe auto-inflammatory sequelae. Principally a failure of IL-10 producing regulatory B cells as demonstrated through functional ex vivo assays and deep phenotyping mass cytometric analysis, is a major and significant finding in patients who develop high-grade irAEs when undergoing treatment with anti-PD1/PD-L1 checkpoint blockade. There is currently a lack of biomarkers to identify a priori those patients at greatest risk of developing severe auto-inflammatory syndrome. Pre-therapy B cell profiling could provide an important tool to identify lung cancer patients at high risk of developing severe irAEs on checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.